Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicenter, randomized, double-blind, placebo-controlled trial will assess the effects of twice-daily subcutaneous injection with exenatide versus treatment with matching placebo injection on abdominal visceral fat content.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

NCT00099320

Type 2 Diabetes Mellitus

COMPLETED PHASE3

Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

NCT03007329

Steatosis, Liver Type2 Diabetes

COMPLETED PHASE4

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

NCT01432405

Type 2 Diabetes Mellitus

COMPLETED PHASE4

An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00135330

Diabetes Mellitus, Type 2

COMPLETED PHASE3

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

NCT03419624

Obesity Diabetes Mellitus, Type 2

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

subcutaneous injection, twice a day

2

Group Type EXPERIMENTAL

exenatide

Intervention Type DRUG

subcutaneous injection, twice a day, 10mcg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

placebo

subcutaneous injection, twice a day

Intervention Type DRUG

exenatide

subcutaneous injection, twice a day, 10mcg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients between 18 and 85 years of age, inclusive.
* Patients with type 2 diabetes
* Patients have been treated with metformin, at a stable dose for at least 3 months prior to Visit 1
* Patients have HbA1c of 7.0% to 8.9%, inclusive.
* Patients have a body mass index \>27 kg/m2 and \<40 kg/m2 and meet local CT scan body weight requirements. For South Asian, Japanese, and Chinese patients, a body mass index \>=25 kg/m2 is acceptable as the lower limit.
* Patients have a history of stable body weight (not varying by \>2 kg in the 3 months prior to Visit 1).
* Medications for the treatment of high blood pressure are stable with respect to treatment regimen for 4 weeks prior to Visit 1.
* Stable regimen of lipid-lowering agents for 6 weeks prior to Visit 1.

Exclusion Criteria

* Have received treatment in the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
* Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
* Have a history of renal transplantation, or are currently receiving renal dialysis.
* Have had a clinically significant history of cardiac disease or presence of active cardiac disease within 1 year prior to Visit 1, including myocardial infarction, clinically significant arrhythmia, unstable angina, moderate to severe congestive heart failure, coronary artery bypass surgery, or angioplasty; or is expected to require coronary artery bypass surgery or angioplasty during the course of the study.
* Have known hemoglobinopathy or clinically significant, chronic anemia.
* Known or are likely to become transfusion dependent during the study.
* Have active, symptomatic proliferative retinopathy.
* Are receiving chronic treatment for gastrointestinal disease with a drug directly affecting gastrointestinal motility. (i.e. metoclopramide, cisapride, and chronic use of macrolide antibiotics)
* Have severe gastrointestinal disease, including gastroparesis.
* Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 months immediately prior to Visit 1.
* Have taken exenatide, liraglutide or any other GLP-1 receptor agonist in the past 6 months, either in a clinical study or as commercially available medication. Patients with known allergy to exenatide should be excluded.
* Have used any prescription or over the counter drug to promote weight loss within 3 months prior to Visit 1, or intend to use such a drug during the study. (Examples: Xenical \[orlistat\], Meridia \[sibutramine\], Acutrim \[phenylpropanolamine\], Acomplia \[rimonabant\]).
* Have participated in a structured weight loss program within 3 months prior to Visit 1, or intend to participate in such a plan during this study.
* Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to Visit 1: Insulin; Thiazolidinediones; Alpha-glucosidase inhibitors; Sulfonylureas; Oral DPP-IV inhibitors; Meglitinides.
* Are taking warfarin, or a coumarol derivative.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No